Skip to main content
. 2023 Dec 5;330(21):2064–2074. doi: 10.1001/jama.2023.19918

Figure 2. Overall Survival.

Figure 2.

For patients with a combined positive score (CPS) of 5 or more, the median follow-up for overall survival was 19.4 (IQR, 14.1-23.2) months for sintilimab plus chemotherapy and 18.9 (IQR, 13.8-24.5) months for placebo plus chemotherapy; the median overall survival was 18.4 months vs 12.9 months. For all randomized patients, median follow-up for overall survival was 19.3 (IQR, 14.1-22.4) months for sintilimab plus chemotherapy and 18.1 (IQR, 13.5-22.7) months for placebo plus chemotherapy; median overall survival was 15.2 months vs 12.3 months. See Figure 1 legend footnote e for programmed cell death ligand 1 CPS calculations. A CPS of 5 or more was defined as PD-L1 positive.